Research analysts at Goldman Sachs started coverage on shares of Nevro (NYSE:NVRO) in a note issued to investors on Wednesday. The firm set a “neutral” rating and a $83.00 price target on the medical equipment provider’s stock. Goldman Sachs’ target price points to a potential downside of 5.46% from the stock’s current price.
A number of other brokerages also recently commented on NVRO. ValuEngine raised shares of Nevro from a “sell” rating to a “hold” rating in a research note on Monday. Zacks Investment Research downgraded shares of Nevro from a “hold” rating to a “sell” rating in a research note on Wednesday, February 28th. Finally, BMO Capital Markets reissued a “buy” rating and issued a $100.00 price objective on shares of Nevro in a research note on Thursday, December 14th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $97.44.
NYSE:NVRO traded down $0.90 during trading hours on Wednesday, reaching $87.79. The company’s stock had a trading volume of 50,534 shares, compared to its average volume of 346,202. The company has a market capitalization of $2,615.81, a price-to-earnings ratio of -70.95 and a beta of -0.53. Nevro has a 12 month low of $65.00 and a 12 month high of $97.70. The company has a quick ratio of 5.91, a current ratio of 7.61 and a debt-to-equity ratio of 0.58.
In other news, Director Wilfred E. Jaeger sold 10,000 shares of the company’s stock in a transaction on Thursday, March 1st. The stock was sold at an average price of $80.48, for a total transaction of $804,800.00. Following the transaction, the director now directly owns 1,518 shares of the company’s stock, valued at $122,168.64. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Wilfred E. Jaeger sold 14,458 shares of the company’s stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $83.28, for a total value of $1,204,062.24. Following the transaction, the director now directly owns 1,518 shares in the company, valued at $126,419.04. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 234,116 shares of company stock worth $18,913,822. Insiders own 12.10% of the company’s stock.
Several hedge funds have recently modified their holdings of NVRO. Hershey Trust Co. acquired a new position in shares of Nevro during the fourth quarter worth $119,000. Public Employees Retirement Association of Colorado purchased a new stake in shares of Nevro during the fourth quarter valued at $160,000. Los Angeles Capital Management & Equity Research Inc. purchased a new stake in shares of Nevro during the third quarter valued at $211,000. Glenmede Trust Co. NA purchased a new stake in shares of Nevro during the fourth quarter valued at $237,000. Finally, HBK Investments L P purchased a new stake in shares of Nevro during the fourth quarter valued at $255,000.
ILLEGAL ACTIVITY NOTICE: “Goldman Sachs Initiates Coverage on Nevro (NVRO)” was originally published by Ticker Report and is the property of of Ticker Report. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.tickerreport.com/banking-finance/3335293/goldman-sachs-initiates-coverage-on-nevro-nvro.html.
Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.
Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.